New mRNA flu vaccine passes first safety check in healthy adults
NCT ID NCT06179446
First seen Nov 16, 2025 · Last updated Apr 30, 2026 · Updated 25 times
Summary
This study tested a new mRNA vaccine designed to protect against a future flu pandemic. Researchers gave the vaccine or a placebo to 157 healthy adults aged 18-49 and 65-84. The main goal was to check safety and see how the immune system responded. Results will help decide if larger studies are needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NYU Langone Health
New York, New York, 10016, United States
-
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, 06511, United States
-
Research Centers of America
Hollywood, Florida, 33024, United States
Conditions
Explore the condition pages connected to this study.